Ceftolozane-Tazobactam Combination Therapy Compared to Ceftolozane-Tazobactam Monotherapy for the Treatment of Severe Infections: A Systematic Review and Meta-Analysis

Ceftolozane-Tazobactam Combination Therapy Compared to Ceftolozane-Tazobactam Monotherapy for the Treatment of Severe Infections: A Systematic Review and Meta-Analysis

Ceftolozane-tazobactam (C/T) is a combination of an advanced-generation cephalosporin (ceftolozane) with a β-lactamase inhibitor (tazobactam). It is approved for the treatment of complicated urinary-tract/intra-abdominal infections and hospital-acquired/ventilator-associated pneumonia. This systemat...

Full description

Bibliographic Details
Main Authors:	Marco Fiore, Antonio Corrente, Maria Caterina Pace, Aniello Alfieri, Vittorio Simeon, Mariachiara Ippolito, Antonino Giarratano, Andrea Cortegiani
Format:	Article
Language:	English
Published:	MDPI AG 2021-01-01
Series:	Antibiotics
Subjects:	<i>pseudomonas aeruginosa</i> ESBLs multidrug resistance β-lactamase inhibitors anti-infective agents bacteremia
Online Access:	https://www.mdpi.com/2079-6382/10/1/79

Similar Items

Ceftolozane-tazobactam and ceftazidime-avibactam activity against β-lactam-resistant Pseudomonas aeruginosa and extended-spectrum β-lactamase-producing Enterobacterales clinical isolates from U.S. medical centres
by: Elizabeth B. Hirsch, et al.
Published: (2020-09-01)

Critical evaluation of ceftolozane–tazobactam for complicated urinary tract and intra-abdominal infections
by: Giancola SE, et al.
Published: (2016-05-01)

Ceftazidime/Avibactam and Ceftolozane/Tazobactam for Multidrug-Resistant Gram Negatives in Patients with Hematological Malignancies: Current Experiences
by: Marianna Criscuolo, et al.
Published: (2020-02-01)

Ceftolozane/Tazobactam for Resistant Drugs <i>Pseudomonas aeruginosa</i> Respiratory Infections: A Systematic Literature Review of the Real-World Evidence
by: Luca Gregorio Giaccari, et al.
Published: (2021-05-01)

Efflux Pump AcrAB Confers Decreased Susceptibility to Piperacillin–Tazobactam and Ceftolozane–Tazobactam in Tigecycline-Non-Susceptible Klebsiella pneumoniae
by: Li J, et al.
Published: (2020-11-01)

A Novel β-lactam/β-lactamase Inhibitor: Ceftolozane/tazobactam
by: Kıvanç ŞEREFHANOĞLU
Published: (2019-12-01)

Deciphering the Evolution of Cephalosporin Resistance to Ceftolozane-Tazobactam in Pseudomonas aeruginosa
by: Melissa D. Barnes, et al.
Published: (2018-12-01)

Ceftolozane/tazobactam and ceftazidime/avibactam for the treatment of complicated intra-abdominal infections
by: Goodlet KJ, et al.
Published: (2016-12-01)

Ceftolozane-Tazobactam Treatment of Hypervirulent Multidrug Resistant <i>Pseudomonas aeruginosa</i> Infections in Neutropenic Patients
by: Paolo E. Coppola, et al.
Published: (2020-12-01)

Real-world use of ceftolozane/tazobactam: a systematic literature review
by: Laura Puzniak, et al.
Published: (2021-04-01)

Ceftolozane/tazobactam for the treatment of complicated intra-abdominal and urinary tract infections: current perspectives and place in therapy
by: Escolà-Vergé L, et al.
Published: (2019-07-01)

Ceftolozane/Tazobactam and Ceftazidime/Avibactam for Multidrug-Resistant Gram-Negative Infections in Immunocompetent Patients: A Single-Center Retrospective Study
by: Rosario Cultrera, et al.
Published: (2020-09-01)

Monotherapy of ceftazidime–avibactam and ceftolozane–tazobactam against multidrug-resistant organisms
by: Adnan Alatoom
Published: (2017-09-01)

Ceftolozane/tazobactam – the "new player" in a battle against multiresistant pathogens
by: Golub A.V., et al.
Published: (2018-11-01)

In Vitro Activity of Ceftolozane/tazobactam and Ceftazidime/avibactam Against Carbapenemase-producing Pseudomonas aeruginosa
by: Özlem AYDEMİR, et al.
Published: (2019-12-01)

Ceftolozane/Tazobactam Dosing Requirements Against Bacteremia
by: Jesus Ruiz, et al.
Published: (2020-01-01)

Ceftolozane/tazobactam versus meropenem in patients with ventilated hospital-acquired bacterial pneumonia: subset analysis of the ASPECT-NP randomized, controlled phase 3 trial
by: Jean-François Timsit, et al.
Published: (2021-08-01)

Treatment of bone and joint infections by ceftazidime/avibactam and ceftolozane/tazobactam: a cohort study
by: Claire Rempenault, et al.
Published: (2021-06-01)

Ceftolozane/tazobactam probability of target attainment and outcomes in participants with augmented renal clearance from the randomized phase 3 ASPECT-NP trial
by: Andrew F. Shorr, et al.
Published: (2021-10-01)

Whole Genome Sequencing of Ceftolozane-Tazobactam and Ceftazidime-Avibactam Resistant Pseudomonas aeruginosa Isolated from a Blood Stream Infection Reveals VEB and Chromosomal Metallo-Beta Lactamases as Genetic Determinants: A Case Report
by: Alamri AM, et al.
Published: (2020-11-01)

Integrated Genome-Wide Analysis of an Isogenic Pair of <i>Pseudomonas aeruginosa</i> Clinical Isolates with Differential Antimicrobial Resistance to Ceftolozane/Tazobactam, Ceftazidime/Avibactam, and Piperacillin/Tazobactam
by: Weihua Huang, et al.
Published: (2020-02-01)

Ceftazidime-Avibactam Combination Therapy Compared to Ceftazidime-Avibactam Monotherapy for the Treatment of Severe Infections Due to Carbapenem-Resistant Pathogens: A Systematic Review and Network Meta-Analysis
by: Marco Fiore, et al.
Published: (2020-07-01)

Ceftolozane-tazobactam in combination with fosfomycin for treatment of MDR/XDR P. aeruginosa infective endocarditis
by: A. Prescott, et al.
Published: (2019-10-01)

Chemical Stability of Ceftolozane/Tazobactam in Polyvinylchloride Bags and Elastomeric Pumps
by: Joseph Terracciano, PhD, et al.
Published: (2017-01-01)

Ceftolozane/Tazobactam Resistance and Mechanisms in Carbapenem-Nonsusceptible Pseudomonas aeruginosa
by: Jocelyn Qi-Min Teo, et al.
Published: (2021-02-01)

Ceftolozane/Tazobactam for Treating Children With Exacerbations of Cystic Fibrosis Due to Pseudomonas aeruginosa: A Review of Available Data
by: Silvia Garazzino, et al.
Published: (2020-05-01)

Use of Ceftolozane/Tazobactam in a Case of Septic Shock by Puerperal Sepsis
by: Mario Pezzi, et al.
Published: (2019-01-01)

Evaluation of in vitro activity of ceftolozane–tazobactam against recent clinical bacterial isolates from Brazil – the EM200 study
by: Felipe Francisco Tuon, et al.
Published: (2020-03-01)

In vitro activity of ceftolozane–tazobactam and ceftazidime–avibactam against clinical isolates of meropenem-non-susceptible Pseudomonas aeruginosa: A two-centre study
by: Hasan Cenk Mirza, et al.
Published: (2020-03-01)

Antimicrobial activity of ceftolozane/tazobactam tested against contemporary (2015–2017) Pseudomonas aeruginosa isolates from a global surveillance programme
by: Dee Shortridge, et al.
Published: (2020-06-01)

Early Treatment Outcomes for Bloodstream Infections Caused by Potential AmpC Beta-Lactamase-Producing Enterobacterales with Focus on Piperacillin/Tazobactam: A Retrospective Cohort Study
by: Lena Herrmann, et al.
Published: (2021-06-01)

Experience With Ceftolozane-Tazobactam for the Treatment of Serious Infections in Saudi Tertiary Care Center
by: M Bosaeed, et al.
Published: (2020-02-01)

Profile of ceftolozane/tazobactam and its potential in the treatment of complicated intra-abdominal infections
by: Skalweit MJ
Published: (2015-06-01)

Treatment of Polymicrobial Osteomyelitis with Ceftolozane-Tazobactam: Case Report and Sensitivity Testing of Isolates
by: Jeffrey C. Jolliff, et al.
Published: (2016-01-01)

Ceftolozane/tazobactam: a novel antipseudomonal cephalosporin and β-lactamase-inhibitor combination
by: Hong MC, et al.
Published: (2013-11-01)

Activity of ceftolozane–tazobactam and comparators against Pseudomonas aeruginosa from patients in different risk strata – SMART United States 2016–2017
by: Sibylle H. Lob, et al.
Published: (2020-03-01)

Bloodstream Infection due to Piperacillin/Tazobactam Non-Susceptible, Cephalosporin-Susceptible <i>Escherichia coli</i>: A Missed Opportunity for De-Escalation of Therapy
by: Leah Carlisle, et al.
Published: (2018-12-01)

Evaluation of in vitro activity of ceftolozane-tazobactam in combination with other classes of antibacterial agents against Enterobacterales and Pseudomonas aeruginosa—the EM200 study
by: J. Belkhair, et al.
Published: (2021-05-01)

Activity of ceftolozane/tazobactam against Gram-negative isolates from patients with lower respiratory tract infections – SMART United States 2018–2019
by: James A. Karlowsky, et al.
Published: (2021-03-01)

Ceftolozane–tazobactam for the treatment of osteomyelitis caused by multidrug-resistant pathogens: a case series
by: Xing Tan, et al.
Published: (2019-07-01)